Cryptococcal Pneumonia in a Patient with Rheumatoid Arthritis Treated with Baricitinib

Jia Li,Yuetian Yu,Jingjing Xie,Yan Jiang,Liangjing Lu
DOI: https://doi.org/10.1093/rheumatology/keab658
2022-01-01
Rheumatology
Abstract:Dear Editor, Baricitinib is an oral selective Janus kinase (JAK)1 and JAK2 inhibitor approved for treating patients with RA who have had an inadequate response to conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) [1], and has been investigated in clinical trials for the treatment of autoimmune diseases. However, there is a safety issue with regard to the risk of serious and opportunistic infections in patients using JAK inhibitors [2]. It has been reported that 16.7% of patients treated with baricitinib have suffered from various infections in real-word clinical practice, including herpes zoster infection and severe herpes simplex infection [3, 4]. Here we report a case of cryptococcal pneumonia in a patient with RA after commencing baricitinib treatment. A 72-year-old man presented to the Department of Rheumatology with fever, cough and dyspnoea for four weeks. He had a three-month history of RA without pulmonary...
What problem does this paper attempt to address?